New hope for men with Tough-to-Treat prostate cancer
Disease control
Recruiting now
This study is testing a new targeted radiation drug called FPI-2265 for men with advanced prostate cancer that has spread and is no longer responding to standard hormone treatments. The goal is to find the safest and most effective dose and schedule for this new therapy. The stud…
Phase: PHASE2 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC